XDNA
Strategic CRISPR & Gene Editing Technology Index
Why Exposure to this Index
Strategic CRISPR & Gene Editing Technology Index measures the performance of companies that specialize in DNA modification systems, and technologies, for a variety of applications including basic biological research, development of biotechnological products, and treatment of diseases as well as next-generation sequencing that may be used at various stages of a genome editing workflow.
INDEX DETAILS
Index Name
Strategic CRISPR & Gene Editing Technology Index
|
Index Calculator
Morgate Benchmarks Ltd
|
Weighting Method
Modified Market Cap
|
Rebalance
Quarterly
|
Weighted Avg Market Cap
-
|
Documents
Index Fact Sheet
Download
|
Index Methodology
Download
|
Index Overview
The Strategic CRISPR & Gene Editing Technology Index seeks to provide total return by investing in a passively managed, concentrated portfolio of companies that engage in CRISPR & gene editing technology activities.
- Designed to capitalize on the burgeoning megatrends that are disrupting the genomic and life science industries.
- Targets companies in the US and developed markets that operate across three CRISPR & Gene Editing sub-sectors, including:
- CRISPR & Gene Editing Technology sub-sector: Includes companies that specialize in DNA modification systems, and technologies, for a variety of applications including basic biological research, development of biotechnological products, and for the treatment of diseases. CRISPR & gene editing technology enables genetic elements to be mutated, silenced, induced ore replaced. The most common use of DNA modification technology is the targeting of cells within the body to treat genetic disease.
- Gene Editing Development Solutions sub-sector: Includes companies that have deep scientific, technical and clinical development experience, potentially along with an intellectual property portfolio, that have rights to develop CRISPR or gene-editing based therapeutic products or targets and/or jointly develop potential products with CRISPR & gene editing technology companies to create a new class of therapeutic products.
- Gene Editing Sequencing Solutions sub-sector: Includes companies that specialize in next-generation sequencing that may be used at various stages of a genome editing workflow. The companies provide sequencing methods to determine the impact of an edited sequence on the structured function of genes and analysis tools for CRISPR and gene splicing and editing.
- Companies are initially identified by industry and sector, and are then further reviewed on the basis of operations related to CRISPR & Gene Editing technology activities.
- The index is composed of the 40 or so largest eligible companies using float adjusted capitalization, and the largest companies make up a greater percentage of the overall portfolio.
[NAME] SITE
Thank you for visiting Kelly Intelligence
You are now being redirected to our [NAME] site.